Pharmacy Pearls: Trelegy Ellipta for COPD

December 3rd, 2021 | Asthma/COPD•Pharmacy Pearls

In this edition of Pharmacy Pearls, we review the use of Trelegy Ellipta for COPD, including some of the clinical trial outcomes that demonstrate benefits of triple therapy and which patients might be appropriate for triple therapy. You will also find dosing information and potential benefits for switching patients from multiple inhalers to Trelegy Ellipta.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [164.20 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Trelegy Ellipta for COPD

Pharmacy Pearls: Trelegy Ellipta for COPD

GENERAL COVID-19 INFORMATION